Dogwood Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 8, 2024
DWTX$1.20-6.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Exhibit Index
| ExhibitNo. | Description | |
| | ||
| 2.1 | | Share Exchange Agreement, dated October 7, 2024, relating to Pharmagesic (Holdings) Inc., by and between Virios Therapeutics, Inc. and Sealbond Limited (incorporated by reference herein from Exhibit 2.1 to the Current Report on Form 8-K, filed with the SEC on October 7, 2024). |
| | | |
| 3.1 | | Certificate of Incorporation of Virios Therapeutics, Inc. (incorporated by reference herein from Exhibit 3.1 to the Company’s Registration Statement on Form S-1, filed with the SEC on August 28, 2020) |
| | | |
| 3.2 | | Certificate of Designation of Series A Non-Voting Convertible Preferred Stock of Virios Therapeutics, Inc., dated October 7, 2024 (incorporated by reference herein from Exhibit 3.1 to the Current Report on Form 8-K, filed with the SEC on October 7, 2024). |
| | | |
| 3.3 | | Certificate of Amendment of Certificate of Incorporation of Virios Therapeutics, Inc., as amended, dated October 7, 2024 (incorporated by reference herein from Exhibit 3.2 to the Current Report on Form 8-K, filed with the SEC on October 7, 2024). |
| | | |
| 3.4 | | Amended and Restated By-laws of Dogwood Therapeutics, Inc., dated October 7, 2024 (incorporated by reference herein from Exhibit 3.3 to the Current Report on Form 8-K, filed with the SEC on October 7, 2024). |
| | | |
| 4.1 | | Specimen Certificate evidencing shares of the Registrant’s common stock (incorporated by reference herein from Exhibit 4.1 to the Company’s Registration Statement on Form S-1, filed with the SEC on October 16, 2020). |
| | | |
| 10.1 | | Loan Agreement, dated October 7, 2024, by and between Virios Therapeutics, Inc. and Conjoint, Inc. (incorporated by reference herein from Exhibit 10.1 to the Current Report on Form 8-K, filed with the SEC on October 7, 2024). |
| | | |
| 10.2 | | Registration Rights Agreement, dated October 7, 2024, by and between Virios Therapeutics, Inc. and Sealbond Limited (incorporated by reference herein from Exhibit 10.2 to the Current Report on Form 8-K, filed with the SEC on October 7, 2024). |
| | | |
| 10.3† | | Contingent Value Rights Agreement, dated October 7, 2024, by and between Virios Therapeutics, Inc and Broadridge Corporation Issuer Solutions, LLC a Pennsylvania limited liability company. |
| | | |
| 10.4† | | Form of Stockholder Support Agreement, dated October 7, 2024, by and between the Virios Therapeutics, Inc. and certain stockholders of Virios Therapeutics, Inc. |
| | | |
| 10.5† | | Form of Lock-Up Agreement, dated October 7, 2024, by and between the Virios Therapeutics, Inc. and Sealbond limited. |
| | | |
| 10.6† | | Form of Repurchase Agreement, dated October 7, 2024, by and between the Virios Therapeutics, Inc. and Sealbond limited. |
| | | |
| 31.1† | | Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| |
| 31.2† | | Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
|---|---|---|
| | ||
| 32.1† | | Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| | ||
| 32.2† | | Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| | | |
| 101.INS† | | XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document |
| | ||
| 101.SCH† | | XBRL Taxonomy Extension Schema Document |
| | ||
| 101.CAL† | | XBRL Taxonomy Extension Calculation Linkbase Document |
| | ||
| 101.DEF† | | XBRL Taxonomy Extension Definition Linkbase Document |
| | ||
| 101.LAB† | | XBRL Taxonomy Extension Label Linkbase Document |
| | ||
| 101.PRE† | | XBRL Taxonomy Extension Presentation Linkbase Document |
| | | |
| 104† | | Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) |
| † | Filed herewith. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.